Clinical Trial Update: Lenalidomide Maintenance Post-debulking in Advanced CTCL [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lenalidomide maintenance after debulking in advanced cutaneous T-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Lymphoma | Phase 3 | Status: TERMINATED